Study Results Show Shorter Radiation for Breast Cancer is ‘Worthy of Further Study’
January 11th 2023An expert from the Mayo Clinic notes that there’s also a great amount of interest in further optimizing the dose of radiation after mastectomy, especially in patients with breast cancer immediately following reconstruction.
Viability of Breast Conservation Therapy Gives Patients ‘More of a Choice,’ Says Expert
January 8th 2023Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota indicated that breast conservation therapy, if it can be proven as a reasonable option for patients with multiple ipsilateral breast cancer, could offer patients more choice in treatment.
Shorter Radiation After Mastectomy Could Improve Access for Patients With Breast Cancer
January 7th 2023If feasible, hypofractionated radiation—large doses of radiation given over a shorter period of time than standard radiation—after mastectomy would provide more patients with breast cancer a tissue-sparing option, according to an expert from the Mayo Clinic.
Oncology Peer Review On-The-Go: Experts Share Multidisciplinary Takeaways From 2022 SABCS
December 26th 2022Judy C. Boughey, MD; Robert Mutter, MD; and Siddhartha Yadav, MD, MBBS, of Mayo Clinic spoke with CancerNetwork® multidisciplinary findings presented at the 2022 San Antonio Breast Cancer Symposium, ranging from surgery to radiotherapy to biomarker research.
OS and EFS Improved With Neoadjuvant Chemotherapy/Carboplatin for Locally Advanced TNBC
December 10th 2022Patients with operable, locally advanced triple-negative breast cancer experienced notable improvements in survival following treatment with neoadjuvant carboplatin plus sequential taxane-anthracycline neoadjuvant chemotherapy.
Capivasertib Plus Fulvestrant Yields PFS Improvement in HR+/HER2– Breast Cancer
December 8th 2022Results from the phase 3 CAPItello-291 trial indicated that the combination of capivasertib plus fulvestrant produced improved progression-free survival in patients who have hormone-receptor–positive/HER2-negative advanced breast cancer.